First, from a therapeutical point of view, GRK2-biased β2AR agonists may represent a promising, orally available alternative to current type 2 diabetes and obesity treatments, although it should be noted that evidence of clinical efficacy in patients has not yet been demonstrated. Here, ADRB2 is linked to obesity due to melanocortin 4 receptor deficiency.